Safety and tolerability of adjunctive eslicarbazepine acetate in adolescents with focal-onset seizures: Data from three double-blind, placebo-controlled randomized clinical studies

Adolescence is a critical developmental period in which major metabolic changes occur.1 We aimed at evaluating safety and tolerability of adjunctive eslicarbazepine acetate (ESL) in adolescents (ages 12–18) with refractory focal-onset seizures.